Exercise in a Pill Is Now in Human Trials - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

  • By

  • Kerri Miller

  • March 18, 2026

  • 2 min

Share

  • 1

    ATR-258 is an oral compound designed to replicate exercise's metabolic effects, including fat loss and muscle preservation.

  • 2

    The compound is a GRK2-biased β2-agonist, selectively activating muscle-building signaling without cardiovascular side effects.

  • 3

    An 8-week human trial at the University of Copenhagen is focused on muscle physiology data in overweight male volunteers.

  • 4

    The study aims to address muscle-sparing weight loss, filling a gap left by current GLP-1 obesity treatments.

  • 5

    Results from the trial are expected later this year, with questions remaining about generalizability and long-term outcomes.

Original Source(s)

Exercise in a Pill Is Now in Human Trials

  • by Kerri Miller

  • March 18, 2026

Related Content

Volatility priors may reveal delusion severity in schizophrenia

Expectations of environmental instability declined alongside delusional symptoms during 6 months following an acute psychotic episode.

Ovulation may shift preferences toward conspicuous luxury

Across 3 studies, higher fertility was associated with greater preference for luxury when it was visible, personally relevant, and potentially noticeable to others.

Does portal writing style contribute to disparities in clinician response?

Message length, punctuation, and clinician greetings were associated with intended clinician response.